$117.2 M

TNXP Mkt cap, 23-Sept-2020
Tonix Pharmaceuticals Net income (Q2, 2020)-14.2 M
Tonix Pharmaceuticals EBIT (Q2, 2020)-14.2 M
Tonix Pharmaceuticals Cash, 30-Jun-202055 M
Tonix Pharmaceuticals EV63.1 M

Tonix Pharmaceuticals Income Statement

Tonix Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

41.1k1.8m8.2m38.2m19.2m18.9m25.5m25.0m11.2m

Accounts Receivable

598.6m

Prepaid Expenses

102.4k224.7k429.0k852.0k3.3m947.0k1.0m2.7m

Current Assets

143.6k2.0m8.6m39.0m46.4m27.1m26.4m26.1m13.9m

PP&E

25.6k46.9k45.0k328.0k350.0k150.0k91.0k43.0k34.0k

Total Assets

425.4k2.1m8.7m39.5m47.0m27.5m26.8m26.3m14.6m

Accounts Payable

695.2k825.8k765.0k1.5m3.0m872.0k1.3m1.4m3.1m

Short-term debt

150.0k352.0k

Current Liabilities

925.3k1.1m2.2m3.4m6.7m2.1m2.1m2.7m5.1m

Long-term debt

1.9m6.0k

Total Debt

2.1m358.0k

Total Liabilities

2.9m1.2m2.2m3.5m6.8m2.1m2.1m2.7m5.1m

Common Stock

27.1k2.2k6.0k11.0k19.0k8.0k3.0k9.0k

Preferred Stock

Additional Paid-in Capital

3.9m16.8m33.2m90.4m142.7m166.6m187.0m212.2m226.5m

Retained Earnings

(54.3m)(102.4m)(141.2m)(162.4m)(188.5m)(217.1m)

Total Equity

(2.5m)958.7k6.5m36.1m40.3m25.4m24.6m23.7m9.4m

Financial Leverage

-0.2 x2.2 x1.3 x1.1 x1.2 x1.1 x1.1 x1.1 x1.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

747.0205.02.5m1.3m35.7k423.7k68.0k7.4m49.5m43.9m46.2m58.2m48.7m33.0m8.4m14.9m15.6m19.9m34.4m29.3m19.3m16.7m14.7m16.4m12.2m10.0m30.7m55.0m

Prepaid Expenses

64.0k74.5k43.1k67.7k46.4k46.4k554.0k946.0k699.0k1.8m1.6m2.1m3.2m2.4m2.5m1.0m1.1m896.0k1.4m1.4m1.1m2.7m2.0m1.5m2.7m2.6m

Current Assets

2.6m1.4m78.7k491.4k114.4k7.5m50.1m44.8m46.9m60.0m50.3m57.2m30.7m33.7m29.2m23.4m35.5m30.2m20.7m18.2m15.9m19.2m14.2m11.6m33.4m57.6m

PP&E

23.2k53.2k51.0k42.8k38.8k42.8k43.0k71.0k224.0k306.0k316.0k327.0k383.0k349.0k315.0k132.0k118.0k102.0k78.0k65.0k55.0k41.0k36.0k34.0k28.0k37.0k

Total Assets

747.0205.02.6m1.5m190.0k594.5k314.4k7.6m50.2m45.1m47.3m60.5m50.9m57.8m31.3m34.3m29.8m23.8m35.8m30.5m21.0m18.4m16.1m20.0m15.0m12.3m33.9m58.3m

Accounts Payable

182.4k486.9k697.4k870.1k1.5m985.8k1.4m1.5m2.4m2.0m2.8m2.4m2.1m1.9m944.0k841.0k1.2m1.4m1.3m1.6m1.1m1.1m1.0m1.1m1.4m3.2m

Short-term debt

256.0k346.0k

Current Liabilities

284.3k782.8k836.8k1.2m2.3m2.1m2.3m2.4m3.5m3.5m4.6m5.1m3.9m4.2m2.6m1.8m1.8m1.8m2.4m2.5m2.3m2.0m2.0m2.4m2.7m4.7m

Long-term debt

200.0k139.0k51.0k306.0k536.0k

Total Debt

200.0k139.0k51.0k562.0k882.0k

Total Liabilities

13.5k15.2k3.0m810.8k864.3k1.2m2.3m2.1m2.3m2.4m3.6m3.6m4.7m5.2m4.0m4.3m2.7m1.8m1.9m1.9m2.4m2.5m2.3m2.2m2.2m2.4m2.7m4.8m

Common Stock

5.5k34.3k34.3k34.3k2.2k2.2k4.9k10.0k10.0k11.0k16.0k16.0k19.0k19.0k25.0k29.0k4.0k7.0k8.0k8.0k9.0k10.0k6.0k6.0k2.0k49.0k105.0k

Preferred Stock

Additional Paid-in Capital

59.5k59.5k8.0m12.2m12.5m17.2m18.0m28.5m79.8m80.6m89.1m120.9m122.0m141.7m143.7m156.2m160.8m168.3m185.1m185.6m187.9m191.3m194.6m212.5m213.4m218.3m255.6m292.1m

Retained Earnings

(37.9m)(45.4m)(64.0m)(75.8m)(89.0m)(116.4m)(126.2m)(133.8m)(146.3m)(151.1m)(156.9m)(169.3m)(175.4m)(180.9m)(194.7m)(200.5m)(208.4m)(224.3m)(238.5m)

Total Equity

(12.7k)(15.0k)(378.9k)714.9k(674.3k)(639.7k)(2.0m)5.4m47.9m42.7m43.8m56.9m46.2m52.7m27.3m30.0m27.1m22.0m34.0m28.7m18.6m15.8m13.7m17.8m12.8m9.9m31.2m53.6m

Financial Leverage

-0.1 x0 x-7 x2.1 x-0.3 x-0.9 x-0.2 x1.4 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.1 x1.2 x1.2 x1.1 x1.1 x

Tonix Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.5k)(2.3k)(2.0m)(5.1m)(6.8m)(2.0m)(4.1m)(7.2m)(5.2m)(11.2m)(18.6m)(9.7m)(21.4m)(34.7m)(14.0m)(23.8m)(31.4m)(5.1m)(9.8m)(15.6m)(6.9m)(13.0m)(18.5m)(6.2m)(12.1m)(19.9m)(7.3m)(21.5m)

Depreciation and Amortization

2.4k6.1k10.2k4.1k8.1k12.2k4.0k9.0k15.0k22.0k45.0k90.0k57.0k113.0k163.0k24.0k34.0k50.0k15.0k30.0k43.0k9.0k16.0k21.0k6.0k12.0k

Accounts Payable

(512.8k)(208.3k)2.2k44.3k635.4k160.0k635.0k754.0k1.7m502.0k1.3m948.0k(986.0k)(1.1m)(2.1m)(31.0k)307.0k490.0k(32.0k)342.0k(249.0k)(270.0k)(358.0k)(285.0k)(1.7m)118.0k

Cash From Operating Activities

(1.8m)(2.9m)(4.2m)(1.4m)(2.1m)(5.0m)(4.1m)(9.8m)(14.6m)(9.1m)(18.3m)(30.6m)(15.5m)(23.5m)(31.9m)(4.8m)(9.2m)(14.2m)(6.8m)(12.3m)(17.1m)(8.6m)(13.4m)(20.0m)(9.3m)(19.4m)

Purchases of PP&E

(33.8k)(35.7k)(8.1k)(2.0k)(35.0k)(194.0k)(33.0k)(68.0k)(65.0k)(66.0k)(66.0k)(2.0k)(2.0k)(2.0k)(4.0k)(7.0k)(7.0k)(10.0k)(12.0k)(14.0k)

Cash From Investing Activities

(22.0)(33.9k)(35.7k)(22.0)(45.0)(8.2k)(2.0k)(107.0k)(267.0k)(153.0k)(22.2m)4.7m7.5m12.7m4.7m7.2m7.2m(2.0k)(4.0k)(7.0k)(7.0k)(10.0k)(12.0k)(14.0k)

Cash From Financing Activities

4.2m4.2m4.2m405.8k10.6m45.4m45.5m52.9m29.1m29.0m47.7m11.8m15.6m1.1m17.4m17.4m532.0k3.5m6.4m70.0k490.0k5.0m28.8m63.2m

Net Change in Cash

2.5m1.3m(5.5k)(1.4m)(1.7m)5.6m41.3m35.7m38.0m20.0m10.6m(5.2m)(10.7m)(4.2m)(3.5m)1.0m15.4m10.4m(6.2m)(8.8m)(10.8m)(8.6m)(12.9m)(15.0m)19.4m43.8m

Interest Paid

35.2k35.2k35.2k3.2k3.1k3.1k

Tonix Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

-0.1 x